Cargando…

A Pharmacokinetics, Efficacy, and Safety Study of Gadoterate Meglumine in Pediatric Subjects Aged Younger Than 2 Years

OBJECTIVES: The primary objective of this study was to investigate the pharmacokinetic profile of gadoterate meglumine in pediatric patients younger than 2 years; the secondary objectives were to document its efficacy and safety. MATERIAL AND METHODS: This was a Phase IV open-label, prospective stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scala, Mario, Koob, Meriam, de Buttet, Sophie, Bourrinet, Philippe, Felices, Mathieu, Jurkiewicz, Elzbieta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768226/ https://www.ncbi.nlm.nih.gov/pubmed/28906338 http://dx.doi.org/10.1097/RLI.0000000000000412

Ejemplares similares

Anaphylaxis to gadobutrol and gadoterate meglumine in a patient with low grade astrocytoma
por: Montalvo, Juan Manuel Escobar, et al.
Publicado: (2014)

Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study
por: Soyer, Philippe, et al.
Publicado: (2016)

Gadoterate meglumine decreases ADC values of breast lesions depending on the b value combination
por: Arponen, Otso, et al.
Publicado: (2018)

Safety of gadoterate meglumine in over 1600 children included in the prospective observational SECURE study
por: Chang, De-Hua, et al.
Publicado: (2019)

Comprehensive Speciation Analysis of Residual Gadolinium in Deep Cerebellar Nuclei in Rats Repeatedly Administered With Gadoterate Meglumine or Gadodiamide
por: Strzeminska, Izabela, et al.
Publicado: (2022)

Gadolinium Clearance in the First 5 Weeks After Repeated Intravenous Administration of Gadoteridol, Gadoterate Meglumine, and Gadobutrol to rats
por: Bussi, Simona, et al.
Publicado: (2021)

Gadolinium Retention and Clearance in the Diabetic Brain after Administrations of Gadodiamide, Gadopentetate Dimeglumine, and Gadoterate Meglumine in a Rat Model
por: Wang, Shu-ting, et al.
Publicado: (2019)

Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study)
por: Deray, Gilbert, et al.
Publicado: (2012)

Respiratory anomalies associated with gadoxetate disodium and gadoterate meglumine: compressed sensing MRI revealing physiologic phenomena during the entire injection cycle
por: Glessgen, Carl Guillaume, et al.
Publicado: (2021)

Safety of Gadoterate Meglumine (Gd-DOTA) as a Contrast Agent for Magnetic Resonance Imaging: Results of a Post-Marketing Surveillance Study in Japan
por: Ishiguchi, Tsuneo, et al.
Publicado: (2012)

Lack of evidence of a relationship between magnetic resonance signal intensity changes in the globus pallidus and dentate nucleus, and repeated administrations of gadoterate meglumine in children
por: Lancelot, Eric, et al.
Publicado: (2017)

Single-Dose Gadoterate Meglumine for 3T Late Gadolinium Enhancement MRI for the Assessment of Chronic Myocardial Infarction: Intra-Individual Comparison with Conventional Double-Dose 1.5T MRI
por: Lim, Jiyeon, et al.
Publicado: (2018)

Influence of aging and gadolinium exposure on T1, T2, and T2*-relaxation in healthy women with an increased risk of breast cancer with and without prior exposure to gadoterate meglumine at 3.0-T brain MR imaging
por: Krug, Kathrin Barbara, et al.
Publicado: (2021)

Breast lesion detection and characterization with contrast‐enhanced magnetic resonance imaging: Prospective randomized intraindividual comparison of gadoterate meglumine (0.15 mmol/kg) and gadobenate dimeglumine (0.075 mmol/kg) at 3T
por: Clauser, Paola, et al.
Publicado: (2018)

Transdermal Flunixin Meglumine as a Pain Relief in Donkeys: A Pharmacokinetics Pilot Study
por: McLean, Amy K., et al.
Publicado: (2023)

Pharmacokinetics of flunixin meglumine in mature swine after intravenous, intramuscular and oral administration
por: Pairis-Garcia, Monique D, et al.
Publicado: (2013)

Immuno-pharmacokinetics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis Caused by Leishmania (Viannia)
por: Gómez, María Adelaida, et al.
Publicado: (2020)

Re: Effects of serial macrocyclic-based contrast materials gadoterate meglumine and gadobutrol administrations on gadolinium-related dentate nuclei signal increases in unenhanced T1-weighted brain: a retrospective study in 158 multiple sclerosis (MS) patients
por: Raynaud, Jean-Sébastien, et al.
Publicado: (2018)

Pharmacokinetics, Safety, and Efficacy of Gadopiclenol in Pediatric Patients Aged 2 to 17 Years
por: Jurkiewicz, Elżbieta, et al.
Publicado: (2022)

Pharmacokinetics of Canakinumab in children younger than 2 years old with CAPS
por: Kalabus, J, et al.
Publicado: (2015)

Pharmacokinetics of neutron-irradiated meglumine antimoniate in Leishmania amazonensis-infected BALB/c mice
por: Borborema, Samanta Etel Treiger, et al.
Publicado: (2019)

Pharmacokinetics of Intravenous, Intramuscular, Oral, and Transdermal Administration of Flunixin Meglumine in Pre-wean Piglets
por: Kittrell, Heather C., et al.
Publicado: (2020)

Pharmacokinetics of Transdermal Flunixin Meglumine Following a Single Dose in Marine Toads (Rhinella marina)
por: Scott, Gregory, et al.
Publicado: (2020)

Comparison of Intralesional Meglumine Antimonite along with oral Itraconazole to Intralesional Meglumine Antimonite in the treatment of Cutaneous Leishmaniasis
por: Bashir, Uzma, et al.
Publicado: (2019)

Incidental Intrathecal Injection of Meglumine Diatrizoate
por: Masjedi, Mansour, et al.
Publicado: (2014)

FIRST REPORT ON OTOTOXICITY OF MEGLUMINE ANTIMONIATE
por: Valete-Rosalino, Cláudia Maria, et al.
Publicado: (2014)

Tafamidis and tafamidis meglumine for amyloid cardiomyopathy
Publicado: (2021)

Posterior Vitreous Detachment in Normal Healthy Subjects Younger Than Age Twenty
por: Hayashi, Ayumi, et al.
Publicado: (2021)

Inductively coupled plasma mass spectrometry method for plasma and intracellular antimony quantification applied to pharmacokinetics of meglumine antimoniate
por: Garay-Baquero, Diana J, et al.
Publicado: (2021)

Pharmacometabolomics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis
por: Vargas, Deninson Alejandro, et al.
Publicado: (2019)

Hoigne Syndrome Caused by Intralesional Meglumine Antimoniate
por: Guarneri, Claudio, et al.
Publicado: (2017)

Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis
por: Berger, Brandon A., et al.
Publicado: (2017)

Radiographic Outcomes of Upper Cervical Fusion for Pediatric Patients Younger Than 10 Years
por: Watanabe, Kei, et al.
Publicado: (2017)

Does Age Interfere With Gadolinium Toxicity and Presence in Brain and Bone Tissues?: A Comparative Gadoterate Versus Gadodiamide Study in Juvenile and Adult Rats
por: Fretellier, Nathalie, et al.
Publicado: (2019)

Are saltmarshes younger than mangrove swamps?
por: Vermeij, Geerat J.
Publicado: (2022)

MR imaging of hepatocellular carcinoma: prospective intraindividual head-to-head comparison of the contrast agents gadoxetic acid and gadoteric acid
por: Collettini, Federico, et al.
Publicado: (2022)

Pulmonary Function Testing in Pediatric Pneumonia Patients With Wheezing Younger Than 3 Years of Age
por: Chen, Jichang, et al.
Publicado: (2019)

Half-marathoners are younger and slower than marathoners
por: Knechtle, Beat, et al.
Publicado: (2016)

Management of a case of accidental intrathecal administration of meglumine diatrizoate
por: Chirumamilla, Vikramaditya, et al.
Publicado: (2012)

Ultra-Long Pharmacokinetic Properties of Insulin Degludec are Comparable in Elderly Subjects and Younger Adults with Type 1 Diabetes Mellitus
por: Korsatko, S., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_mu165eu8bshjgukt9cc29cb8ti